Advances in Microarray Technology Keynote Speakers

Michael Pawlak Head, University of Tuebingen Dr. Michael Pawlak joined the NMI in 2005 and is heading the Department of Biochemistry and Protein Profiling. In a multidisciplinary environment, scientists develop advanced assay systems and applications for industrial partners. Dr. Pawlak's research is focused on the application of microarrays for proteomic and cancer research, including the study of mechanisms of disease and drug action, and the identification of biomarkers for use in personalized medicine. He is offering protein profiling services to pharmaceutical industry and clinical research using Reverse Phase Protein Arrays for the analysis of protein signaling networks. Before Dr. Pawlak was at Novartis Pharma AG and co-founder of Zeptosens AG, and was pioneering sensitive planar waveguide technology for use with Reverse Phase Protein Arrays.
Markus Templin Head, University of Tuebingen Dr. Templin heads the Department of Assay Development at the NMI. In a multidisciplinary environment scientists from applied physics, chemistry, biology and biochemistry are working together to develop advanced assay system for industrial clients. Dr Templin’s research is focused on the application of microarrays for proteomic and cancer research and he holds several patents in this area. Dr. Templin studied biology at the University of Tübingen, did his postdoctoral research at Edinburgh University, Scotland and the Max-Planck-Institute for Developmental Biology, Germany before joining the Natural and Medical Sciences Institute.
Christer Wingren Associate Professor And Lecturer, Lund University Dr. Wingren is a lecturer at the Dept. of Immunotechnology, Lund University, Sweden. Currently, Dr. Wingren directs a research group working on the development of recombinant antibody microarrays for high-throughput disease proteomics (“unlocking biomarker discovery”), with a particular focus on oncoproteomics and autoimmunity. The research is conducted in a translational manner, going from the bed-to-bench and back again, with the long-term goal to define serum, plasma, and urine biomarkers for disease diagnosis, prognosis, and classification. In 2003, he was promoted to Associate Professor in Immunotechnology. Prior to joining Immunotechnology in 1999, Dr. Wingren pursued his post-doctoral training in structural biology in the laboratory of Prof. Ian Wilson at the Scripps Research Institute, La Jolla, USA (1997-1999). Dr. Wingren received his Ph.D. in biochemistry at Lund University in 1997, and a B.Sc. in chemistry in 1991.